{"id":243660,"date":"2026-09-04T17:05:35","date_gmt":"2026-09-04T22:05:35","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/09\/t-cell-therapy-shows-promise-in-treating-aggressive-brain-cancer"},"modified":"2026-09-04T17:05:35","modified_gmt":"2026-09-04T22:05:35","slug":"t-cell-therapy-shows-promise-in-treating-aggressive-brain-cancer","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/09\/t-cell-therapy-shows-promise-in-treating-aggressive-brain-cancer","title":{"rendered":"T Cell Therapy Shows Promise in Treating Aggressive Brain Cancer"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/t-cell-therapy-shows-promise-in-treating-aggressive-brain-cancer.jpg\"><\/a><\/p>\n<p>Furthermore, the researchers observed that in over half of the participants, the tumors stopped growing or reduced in size for as long as three years post-treatment\u2014including one participant whose cancer has remained to this day in complete remission. B7-H3-targeting CAR-T cell therapy could bring new hope to patients living with treatment-resistant recurrent glioblastomas who currently have few, if any, options, the team says.<\/p>\n<p>\u201cWe are excited about figuring out how to treat currently untreatable cancers,\u201d says <a href=\"https:\/\/medicine.yale.edu\/immuno\/profile\/lieping-chen\/\" target=\"_blank\">Lieping Chen, MD, PhD<\/a>, United Technologies Corporation Professor in Cancer Research and professor of immunobiology and of medicine at Yale School of Medicine and one of the study\u2019s co-principal investigators.<\/p>\n<p>Collaborators on the study included a neurosurgical team at Beijing Tiantan Hospital led by Nan Ji, MD, and a team led by Gangxiong Huang, MD, at Tcelltech, a biotech company preparing clinical grade CAR-T cells.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Furthermore, the researchers observed that in over half of the participants, the tumors stopped growing or reduced in size for as long as three years post-treatment\u2014including one participant whose cancer has remained to this day in complete remission. B7-H3-targeting CAR-T cell therapy could bring new hope to patients living with treatment-resistant recurrent glioblastomas who currently [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,47],"tags":[],"class_list":["post-243660","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-neuroscience"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/243660","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=243660"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/243660\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=243660"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=243660"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=243660"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}